The Primary Ciliary Dyskinesia Market is expected to reach USD 528.5 Million by 2030 at 8.6% CAGR during the forecast period 2022-2030. Primary ciliary dyskinesia (PCD), also kown as immotile ciliary syndrome or Kartagener syndrome. Primary ciliary dyskinesia is a rare disorder and is a type of chronic respiratory tract infections, normally occurs in internal organs of human body. The major symptoms of this condition are caused by abnormal cilia and flagella. Normally cilia are microscopic, finger-like projections that stick out from the surface of cells. They are found in the linings of the airway, the reproductive system, and other organs and tissues. Flagella are tail-like structures, similar to cilia that propel sperm cells forward.
In some cases, mutations in the genes can cause primary ciliary dyskinesia result in defective cilia that move abnormally or are unable to move. As cilia have many important functions within the body, defects in these cell structures cause diseased condition
Increasing prevalence of respiratory tract diseases is one of the major factors for the growth of the primary ciliary dyskinesia market during the forecast period. According to the Centers for Disease Control and Prevention (2014), 9.3 million adults diagnosed with respiratory problems. Whereas, 147,101 deaths occurred due to chronic lower respiratory diseases.It is predicted to be the 3rd most death causing factor.
According to the World Health Organization (WHO), over 7 million deaths occur each year of which more than 6 million deaths result from direct use of tobacco. Moreover, According to Eurostat’s, (2014), COPD (Chronic Obstructive Pulmonary Disease) affected more than 200 million people worldwide and is one of the major diseases whose prevalence is increasing across the globe.
However, high cost of the current treatment methods and lack of awareness about rare respiratory diseases such as primary ciliary dyskinesia may hamper the primary ciliary dyskinesia market growth over the review period.
Key Players Some of the key players in primary ciliary dyskinesia market are AstraZeneca, Boehringer Ingelheim GmbH, GlaxoSmithKline, Novartis AG, Pfizer Inc., Teva UK Limited, Masimo Corporation (U.S.), BD (U.S.), Portex Division of Smith Industries Medical System, Teruma Medical Corporation, HTL STREFA SA, Greinier Bio One International GmBH., F. Hoffman La Roche AG, Bayer AG., Acare Technology Co., Medline Industries Inc., Ltd., Hill-Rom Holdings Inc., Allied Healthcare Inc., Rotech Healthcare Inc., and others.
Market Segmentation The primary ciliary dyskinesia market is segmented on the basis of diagnosis, treatment, and end user.
On the basis of diagnosis, the primary ciliary dyskinesia market is segmented into genetic testing, electron microscopy, and others.
On the basis of treatment, the primary ciliary dyskinesia market is categorized into drug treatment, radiotherapy, chemotherapy, others. On the basis of drug treatment, it is further segmented into clarithromycin, erythromycin and azithromycin, and others.
On the basis of end user, the primary ciliary dyskinesia market is segmented into hospitals & clinics, research centers, and others.
Regional Analysis The Americas dominates the primary ciliary dyskinesia market owing to the presence of strong economic condition, huge development in healthcare domain, and focus of research institutions on updating technology for rare diseases diagnosis and treatment methods. Moreover, advanced hospitals infrastructures, availability of skilled healthcare professional are boosting the growth of the primary ciliary dyskinesia market.
Europe holds the second largest primary ciliary dyskinesia market across the globe due to encouraging government policies for research & development and healthcare professionals by various European countries such as France and Germany. Moreover, according to Eurostat’s, (2014), over 401000 deaths were caused by respiratory system diseases, which are equivalent to 8.0 % of all deaths. Proportion of deaths in the UK from respiratory diseases is considerably higher than the other European countries, which will drive the market growth in this region during the forecast period.
Asia Pacific is the fastest growing market owing to more number of developing nations present in this region, for instance, countries like India, china are encouraging the growth of the healthcare domain. Furthermore, increasing patient population from respiratory diseases in developing countries will directly increase the demand for various treatment methods and will boost the growth of the primary ciliary dyskinesia market.
The Middle East & Africa is expected to hold the least market share due to less availability of medical facilities, and less development in the healthcare domain. However, countries such as Qatar and Kuwait are focusing more in healthcare domain and developing medical facilities, which will boost the primary ciliary dyskinesia market growth in this region.
|Market Size||USD 528.5 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Diagnosis, Treatment, and End User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||AstraZeneca, Boehringer Ingelheim GmbH, GlaxoSmithKline, Novartis AG, Pfizer Inc., Teva UK Limited, Masimo Corporation (U.S.), BD (U.S.), Portex Division of Smith Industries Medical System, Teruma Medical Corporation, HTL STREFA SA, Greinier Bio One International GmBH., F. Hoffman La Roche AG, Bayer AG., Acare Technology Co., Medline Industries Inc., Ltd., Hill-Rom Holdings Inc., Allied Healthcare Inc., Rotech Healthcare Inc., and others|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||Increasing prevalence of respiratory tract diseases|